Lymphoma

A friend at the chemotherapy clinic told his story, but never said a word.

Patient education and coordination from the care team are two vital aspects in delivering successful CAR T therapy.

Axicabtagene ciloleucel had high response rates in patients with non-Hodgkin lymphoma in a phase 2 study.

Getting dates while getting Adriamycin.

Your methods of coping with cancer might not always be sexy.

One quirky trick to cut down on hair loss from chemo made me detest refrigerators for life!

Please, If I could just complain, I mean explain, this whole after-treatment thing.

A bone marrow transplant story that even chemobrain won't let me forget.

Axicabtagene ciloleucel can lead to complete remission for patients with refractory diffuse large B-cell lymphoma, according to a recent study.

Car T-Cell therapy is being explored in multiple approaches to treat hematologic malignancies.

Cancer is really difficult, but if you look hard enough, you might find the perks.

Surviving cancer sometimes means re-imagining the life you dreamed about but never thought you would have.

Group exercise programs are beneficial to survivors of cancer, and can offer motivation from peers to continue living a healthy lifestyle.

John P. Leonard, M.D. spoke with CURE about some upcoming advancements in the treatment of follicular lymphoma.

Adding Ibrance to Imbruvica may be a promising treatment strategy for patients with mantle cell lymphoma, according to a recent study.

A recent study examined if the benefit from the drug brentuximab vedotin was worth the neuropathy that it causes for many patients with lymphoma.

Imbruvica was granted an accelerated FDA approval to treat some patients with marginal zone lymphoma (MZL).

Imbruvica (ibrutinib) improved survival for patients with small lymphocytic lymphoma (SLL) and chronic lymphocytic leukemia (CLL), according to study results that were recently presented.

Andrew D. Zelenetz, M.D., Ph.D. weighs in on recent research and the future of treating hematologic malignancies.

Stem cell transplant is still the only curative treatment option for many hematologic malignancies, even as novel drugs continue to emerge.

Patients and providers shared inspiring stories of hope, as well as some tips for better living at the Seventh Annual Ruesch Center Symposium: Fighting a Smarter War on Cancer.

Keytruda was granted a priority review to a supplemental biologics license application (sBLA) to treat a subset of patients with classical Hodgkin lymphoma.

While Opdivo is currently the only immunotherapy agent approved for Hodgkin lymphoma, immunotherapy strategies are beginning to emerge in other indications in the field.

CURE spoke with an expert on the importance of classifying T-cell lymphomas and what is next in this field.

Patients with activated B-cell-like lymphoma may not respond to standard treatment, so new options are being explored.

Updated trial data shows that Opdivo had a high objective response rate for a cohort of patients with classical Hodgkin Lymphoma.

By mitigating some of the financial burdens, The Leukemia & Lymphoma Society helps patients better stick to treatment regimens.

By taking the brakes off immune response, immunotherapy empowers the body to fight resistant or recurrent classical Hodgkin lymphoma.

There’s an enormous — and growing — menu of treatments for B cell lymphomas.